Fenwick & West LLP represented OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients in its public offering of 4,789,750 shares of its common stock at a purchase price of $12.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, were approximately $53.8 million. The offering closed in March 2012.
The Fenwick transaction team included corporate attorneys Alan Smith, James Evans, Amanda Rose and Jen Jinxin Huang.
More information is available from OncoGenex's website: OncoGenex Pharmaceuticals Prices $50 Million Public Offering.